SGLT2 inhibitor, bone metabolism biomarkers, and osteoporosis risk: A Mendelian randomization study

These findings provide genetic support that SGLT2 inhibition increases osteoporosis risk despite raising BMD. Total testosterone does not appear to mediate this relationship, suggesting other pathways or direct skeletal effects drive the observed bone fragility. Further studies are needed to delineate these mechanisms.